Perspective Therapeutics (NYSE:CATX) Earns “Outperform” Rating from Wedbush

Wedbush reaffirmed their outperform rating on shares of Perspective Therapeutics (NYSE:CATX) in a research note issued to investors on Thursday morning,RTT News reports. Wedbush currently has a $11.00 price objective on the stock.

Other analysts have also recently issued reports about the stock. Lifesci Capital upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Saturday, July 12th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Perspective Therapeutics in a report on Friday, September 19th. Finally, B. Riley reiterated a “buy” rating and set a $12.00 price objective (up from $9.00) on shares of Perspective Therapeutics in a research note on Monday, June 23rd. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, Perspective Therapeutics presently has a consensus rating of “Buy” and an average target price of $12.56.

Perspective Therapeutics Stock Performance

Shares of Perspective Therapeutics stock opened at $3.64 on Thursday. Perspective Therapeutics has a 52-week low of $1.60 and a 52-week high of $13.56. The stock’s 50-day simple moving average is $3.53 and its 200 day simple moving average is $3.09.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Affinity Asset Advisors LLC raised its stake in Perspective Therapeutics by 71.1% in the first quarter. Affinity Asset Advisors LLC now owns 2,224,196 shares of the company’s stock valued at $4,738,000 after purchasing an additional 924,196 shares in the last quarter. Nicholson Wealth Management Group LLC increased its holdings in shares of Perspective Therapeutics by 0.3% in the 2nd quarter. Nicholson Wealth Management Group LLC now owns 1,614,283 shares of the company’s stock worth $5,553,000 after buying an additional 5,000 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Perspective Therapeutics by 15.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock valued at $4,758,000 after buying an additional 188,887 shares in the last quarter. Nuveen LLC bought a new stake in shares of Perspective Therapeutics during the 1st quarter worth $2,647,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Perspective Therapeutics by 118.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company’s stock worth $2,573,000 after acquiring an additional 405,612 shares during the last quarter. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.